Join to View Full Profile
227 S 6th StApt PcPhiladelphia, PA 19106
Phone+1 609-240-7312
Dr. Cornfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Emory University School of MedicineResidency, Internal Medicine, 1982 - 1985
Perelman School of Medicine at the University of PennsylvaniaClass of 1982
Certifications & Licensure
PA State Medical License 1985 - 2026
NJ State Medical License 1993 - 2005
GA State Medical License 1983 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Start of enrollment: 2019 Jan 09
Publications & Presentations
PubMed
- 12 citationsNew Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab
Journal for Immunotherapy of Cancer. 2017-06-20 - 127 citationsPhase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.Anthony W. Tolcher, Amita Patnaik, Kyriakos P. Papadopoulos, Drew W. Rasco, Carlos Becerra
Cancer Chemotherapy and Pharmacology. 2015-01-01 - 67 citationsBlockade of interleukin‐6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaSally A. Hunsucker, Valeria Magarotto, Deborah J. Kuhn, Steven M. Kornblau, Michael Wang
British Journal of Haematology. 2011-03-01
Press Mentions
Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-OncolFebruary 24th, 2017- Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 T...November 12th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
